The Ministry of Food and Drug Safety (Director Oh Yu-kyung) announced that it has granted CARVYKTI, a CAR-T treatment agent, a rare drug of Jansen, a rare drug. CAR-T cells are called chimera because they modify the surface receptor to better recognize and attack cancer cells. Carvykti is an anticancer drug that injects the T cell into the patient's body after putting genetic information that can recognize the B cell mature antigen (BCMA) into the patient's immune cells (T cells). B-cell maturity antigen (BCMA) is an ideal target for transplanted cell carcinoma (multiple myeloma) because it is selectively expressed during transformed cell differentiation and is not expressed in other major organs.

Carvy